Inside Immuneering’s New Approach to Cancer Treatment (Ft. Immuneering CEO Ben Zeskind)

Episode 148: Today, Ann is joined by Ben Zeskind, PhD, Co-Founder and CEO of Immuneering. They break down the science behind cancer treatment and how the company’s Deep Cyclic Inhibitors are taking a different approach to pancreatic cancer by targeting not just tumors, but also addressing why treatments fail over time. They also discuss how the technology improves survival rates while maintaining quality of life. Finally, Ben breaks down why biotech stocks don’t always reflect clinical progress, how investors evaluate these companies, and what’s next as Immuneering moves toward late-stage trials.